Long term result of intravitreal bevacizumab in a patient newly transformed to proliferative macular telangiectasia type 2.

Abstract

The clinical and imaging findings and therapeutic outcomes of intravitreal bevacizumab injection in a patient with macular telangiectasia type 2 are described. The patient first presented with the non-proliferative stage of the disease for 4 months, then the disease transformed to the proliferative stage. In the proliferative period, the patient was treated with intravitreal bevacizumab injections as-clinically warranted. Over a follow up period lasting 26 months, the patient received 6 intravitreal bevacizumab injections, the visual acuity improved from 20/100 to 20/40, the central retinal thickness decreased from 318 microns to 198 microns. This case implies that the patients with non-proliferative macular telangiectasia type 2 should be followed carefully for proliferative transformation, and intravitreal bevacizumab treatment seems to be effective for proliferative macular telangiectasia type 2.

• Authors: Abdullah Ozkaya, Zeynep Alkin, Yalcin Karakucuk, Ahmet Taylan Yazici, Ahmet Demirok
• Journal: Middle East African journal of ophthalmology (Middle East Afr J Ophthalmol) 2013 Oct-Dec Vol. 20 Issue 4 Pg. 360-2 ISSN: 0975-1599 [Electronic] India
• PMID: 24339691 (Publication Type: Case Reports, Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• Bevacizumab

Topics

• Angiogenesis Inhibitors (therapeutic use)
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Bevacizumab
• Female
• Fluorescein Angiography
• Follow-Up Studies
• Humans
• Intravitreal Injections
• Middle Aged
• Retinal Neovascularization (diagnosis, drug therapy)
• Retinal Telangiectasis (classification, diagnosis, drug therapy)
• Subretinal Fluid
• Tomography, Optical Coherence
• Treatment Outcome
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Visual Acuity (physiology)